Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.61 |
| ▸ | FER | P16591 | 8/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.51 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20750747 | 1.00 | SYK (0.61) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL20750873 | 0.92 | FER (0.51) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL18926207 | 0.92 | FER (0.51) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL20750878 | 0.91 | SYK (0.50) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL5027996 | 0.90 | SYK (0.74) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL18925611 | 0.89 | SYK (0.47) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL18925343 | 0.88 | SYK (0.49) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL20750834 | 0.88 | SYK (0.49) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL18925841 | 0.88 | SYK (0.46) | SYKFERKCNH2MAPK3MAPK1 | |
| SCHEMBL20750749 | 0.88 | SYK (0.46) | SYKFERKCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | SYK 2450/4885FER 3205/4885KCNH2 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.